Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
diphtheria toxoid + tetanus toxoid + acellular pertussis + hepatitis B recombinant + inactivated poliovirus vaccine
- Development stage
- Approved
- Lead developer
- GSK
- Modality
- Whole Inactivated Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Intramuscular
01
Overview
**diphtheria toxoid + tetanus toxoid + acellular pertussis + hepatitis B recombinant + inactivated poliovirus vaccine** is a pentavalent combination vaccine for infants and young children that protects against five serious infectious diseases: diphtheria, tetanus, pertussis (whooping cough), poliomyelitis, and hepatitis B[1][2][3][7]. The vaccine works by stimulating the immune system to generate protective antibodies against these pathogens. Diphtheria and tetanus components are inactivated (toxoid) bacterial proteins; pertussis is acellular (purified protein subunits); hepatitis B is recombinant (produced via genetic engineering); poliovirus is inactivated (killed virus)[1]. Typically administered as a three-dose series in infants between 6 weeks and 6 years of age, via intramuscular injection[1][2][3]. Primarily indicated for routine pediatric immunization.
- Brand names
- Pediarix
- Other names
- diphtheria and tetanus toxoids and acellular pertussis adsorbed, hepatitis B (recombinant) and inactivated polio vaccineDTap/HepB/IPV vaccine
02
Targets
BCR (Immunoglobulin G B Cell Receptor)Diphtheria toxinHBsAg (Hepatitis B surface antigen)PV3 (Sabin) (Poliovirus type 3 antigen)
Beyond the preview
Go deeper on diphtheria toxoid + tetanus toxoid + acellular pertussis + hepatitis B recombinant + inactivated poliovirus vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on diphtheria toxoid + tetanus toxoid + acellular pertussis + hepatitis B recombinant + inactivated poliovirus vaccine.